Can Genomics Improve Upon Best Clinical Risk Stratification?

Posted by Michael S. Leapman, MD | May 2017

Dr. Michael Leapman presented “Can Genomics Improve Upon Best Clinical Risk Stratification?” at the 22nd Annual Scottsdale Prostate Cancer Symposium on Thursday, March 16, 2017.

How to cite: Leapman, Michael “Can Genomics Improve Upon Best Clinical Risk Stratification?” March 16, 2017. Accessed Apr 2024. https://dev.grandroundsinurology.com/can-genomics-improve-upon-best-clinical-risk-stratification

About The Author

Michael S. Leapman, MD

Dr. Leapman is an Assistant Professor of Urology at the Yale School of Medicine in New Haven, Connecticut. He was drawn to the field of urology by the opportunity to care for patients with urologic cancers. Dr. Leapman graduated from Cornell University, where he majored in Neurobiology and Behavior, and received his medical degree from the University of Maryland in Baltimore. He completed his General Surgery and Urology training at the Mount Sinai Hospital in New York City. Subsequently, he completed a two-year Urologic Oncology Fellowship at the University of California, San Francisco (UCSF), accredited by the Society of Urologic Oncology. He was recruited to join the faculty at the Yale University School of Medicine Smilow Cancer Center in 2016. He specializes in urologic oncology, and has a joint appointment at the West Haven Veterans Affairs Medical Center. His clinical interests include low-risk prostate cancer, active surveillance, nerve-sparing robotic prostatectomy, focal therapy, high-risk disease, and pelvic lymph node dissection.

Join the GRU Community

- Why Join? -

CARDEN JENNINGS PUBLISHING CO., LTD.

Your GRU

– Account Dashboard
– Your Courses

Recent Updates

PDF Embedder Test Jan 2022
Genetic Testing and Prostate Cancer – Welcome Jan 2022
Current Status of PSMA Diagnostics Aug 2021
Genetic Testing and Prostate Cancer Aug 2021
What’s New in Active Surveillance for Prostate Cancer in 2021 Aug 2021

Can Genomics Improve Upon Best Clinical Risk Stratification?

About The Author

Michael S. Leapman, MD

Join the GRU Community

You have Successfully Subscribed!

CARDEN JENNINGS PUBLISHING CO., LTD.

INFO

Your GRU

– Account Dashboard
– Your Courses

Recent Updates

Exercise & Wellness

Can Genomics Improve Upon Best Clinical Risk Stratification?

About The Author

Michael S. Leapman, MD

Related Posts

Biomarkers for Localized Prostate Cancer

The Future of Genomic Markers and DNA Sequencing in Prostate Cancer

Ask the Expert: Are There Genomic Tests to Determine Need for a Repeat Biopsy?

Integrated Multi-Modality Diagnostic Evaluation of Prostate Cancer

Join the GRU Community

You have Successfully Subscribed!

CARDEN JENNINGS PUBLISHING CO., LTD.

INFO

Your GRU

– Account Dashboard – Your Courses

Recent Updates

Exercise & Wellness

– Account Dashboard
– Your Courses